Predicting Radiosensitivity Using DNA End-Binding Complex Analysis

Clinical Cancer Research

Volumn 10, Issue 4, 2004, Pages 1226-1234

  Ismail, Sheikh M ^a   Puppi, Monica ^a   Prithivirajsingh, Sheela ^a   Munshi, Anupama ^a   Raju, Uma ^a   Meyn, Raymond E ^a   Buchholz, Thomas A ^a   Story, Michael D ^a   Brock, William A ^a   Milas, Luka ^a   Thames, Howard D ^a   Stevens, Craig W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DNA STRAND BREAKAGE; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RADIOSENSITIVITY; TUMOR CELL;

CELL LINE; CELL LINE, TUMOR; CELL NUCLEUS; DNA; DNA DAMAGE; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, RADIATION; FIBROBLASTS; HUMANS; MUTATION; NEOPLASMS; RADIATION TOLERANCE;

EID: 12144288745     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0331     Document Type: Article

References (37)

1. Peters, L., and McKay, M. Predictive assays: will they ever have a role in the clinic? Int. J. Radiat. Oncol. Biol. Phys., 49: 501-504, 2001.
2. Tucker, S. L., Geara, F. B., Peters, L. J., and Brock, W. A. How much could the radiotherapy dose be altered for individual patients based on a predictive assay of normal-tissue radiosensitivity? Radiother. Oncol., 38: 103-113, 1996.
3. Mackay, R. I., and Hendry, J. H. The modeled benefits of individualizing radiotherapy patients' dose using cellular radiosensitivity assays with inherent variability. Radiother. Oncol., 50: 67-75, 1999.
4. Burnet, N. G., Nyman, J., Turesson, I., Wurm, R., Yarnold, J. R., and Peacock, J. H. The relationship between cellular radiation sensitivity and tissue response may provide the basis for individualizing radiotherapy schedules. Radiother. Oncol., 33: 228-238, 1994.
5. Burnet, N. G., Warm, R., and Peacock, J. H. Low dose-rate fibroblast radiosensitivity and the prediction of patient response to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 70: 289-300, 1996.
6. MacKay, R. I., Niemierko, A., Goitein, M., and Hendry, J. H. Potential clinical impact of normal tissue intrinsic radiosensitivity testing (letter). Radiother. Oncol., 46: 215-216, 1998.
7. Norman, A., Kagan, A. R., and Chan, S. L. The importance of genetics for the optimization of radiation therapy: a hypothesis. Am. J. Clin. Oncol., 11: 84-88, 1988.
8. Thames, H. D., Schultheiss, T. E., Hendry, J. H., et al. Can modest escalations of dose be detected as increased tumor control? Int. J. Radiat. Oncol. Biol. Phys., 22: 241-246, 1992.
9. Brock, W. A., Baker, F. L., and Peters, L. J. Radiosensitivity of human head and neck squamous cell carcinomas in primary culture and its potential as a predictive assay of tumor radiocurability. Int. J. Radiat. Biol., 56: 751-760, 1989.
10. West, C. M. L., and Hendry, J. H. Intrinsic radiosensitivity as a predictor of patient response to radiotherapy. Br. J. Radiol., 24 (Suppl.): 146-152, 1992.
11. Thacker, J. The nature of mutants induced by ionising radiation in cultured hamster cells. Mutat. Res., 160: 267-275, 1986.
12. Marder, B. A., and Morgan, W. F. Delayed chromosomal instability by DNA damage. Mol. Cell. Biol., 13: 6667-6677, 1993.
13. Hartwell, L. H., and Kasten, M. B. Cell cycle control and cancer. Science (Wash. DC), 266: 182-188, 1994.
14. Karan, P. DNA double strand break repair in mammalian cells. Curr. Opin. Genet. Dev., 10: 144-150, 2000.
15. Nick-McElhinny, S. A., Snowden, C. M., McCarville, J., and Ramsden, D. A. Ku recruits the XRCC4-ligase IV complex to DNA ends. Mol. Cell. Biol., 20: 2996-3003, 2000.
16. Peterson, S. R., Kurimasa, A., Oshimura, M., Dynan, W. S., Bradbury, E. M., and Chen, D. J. Loss of the catalytic subunit of the DNA-dependent protein kinase in DNA double-strand-break-repair mutant mammalian cells. Proc. Natl. Acad. Sci. USA, 92: 3171-3174, 1995.
17. Kurimasa, A., Kumano, S., Boubnov, N. V., Story, M. D., Tung, C-S., Peterson, S. R., and Chen, D. J. Requirement for the kinase activity of human DNA-dependent protein kinase catalytic subunit in DNA strand break rejoining. Mol. Cell. Biol., 19: 3877-3884, 1999.
18. Becker-Catania, S. G., Chen, G., Hwang, M. J., Wang, Z., Sun, X., Sanal, O., Bernatowska-Matuszkiewicz, E., Chessa, L., Lee, E. Y-H. P., and Gatti, R. A. Ataxia-telangiectasia: phenotype/genotype studies of ATM protein expression, mutations, and radiosensitivity. Mol. Genet. Metab., 70: 122-133, 2000.
19. Tchirkov, A., Bay, J-O., Pernin, D., Bignon, Y-J., Rio, P., Grancho, M., Kwiatkowski, F., Giollant, M., Malet, P., and Verrelle, P. Detection of heterozygous carriers of the ataxia-telangiectasia (ATM) gene by G2 phase chromosomal radiosensitivity of peripheral blood lymphocytes. Hum. Genet., 101: 312-316, 1997.
20. Buchholz, T. A., Wu, X., Hussain, A., et al. Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2. Int. J. Cancer, 97: 557-561, 2002.
21. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res., 11: 1475-1489, 1983.
22. Stevens, C. W., Stamato, T. D., Mauldin, S. K., Getts, R. C., Hahn, L. M., Zeng, M., and Cerniglia, G. C. Radiation induced recombination is Ku-80 dependent. Radiat. Res., 151: 408-413, 1999.
23. Weller, G. R., Kysela, B., Roy, R., Tonkin, L. M., Scanlan, E., Della, M., Devine, S. K., Day, J. P., Wilkinson, A., di Adda di Fagagna, F., Devine, K. M., Bowater, R. P., Jeggo, P. A., Jackson, S. P., and Doherty, A. J. Identification of a DNA nonhomologous end-joining complex in bacteria. Science (Wash. DC), 297: 1686-1689, 2002.
24. Ayene, I. S., Stamato, T. D., Mauldin, S. K., Biaglow, J. E., Tuttle, S. W., Jenkins, S. F., and Koch, C. J. Mutation in the glucose-6-phosphate dehydrogenase gene leads to inactivation of Ku DNA end binding during oxidative stress. J. Biol. Chem., 277: 9929-9935.
25. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
26. Johansen, J., Bentzen, S. M., Overgaard, J., and Overgaard, M. Relationship between the in vitro radiosensitivity of skin fibroblasts and the expression of subcutaneous fibrosis, telangiectasia, and skin erythema after radiotherapy. Radiother. Oncol., 40: 101-109, 1996.
27. Brock, W. A., Tucker, S. L., Geara, F. B., Wike, J., Peters, L. J., Turesson, I., and Nyman, J. Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer. Int. J. Radiat. Oncol. Biol. Phys., 32: 1371-1379, 1995.
28. Hart, R. M., Kimler, B. F., Evans, R. G., and Park, C. H. Radiotherapeutic management of medulloblastoma in a pediatric patient with ataxia telangiectasia. Int. J. Radiat. Oncol. Biol. Phys., 13: 1237-1240, 1987.
29. Stausbol-Gron, B., and Overgaard, J. Relationship between tumour cell in vitro radiosensitivity and clinical outcome after curative radiotherapy for squamous cell carcinoma of the head and neck. Radiother. Oncol., 50: 47-55, 1999.
30. Bjork-Eriksson, T., West, C., Karlsson, E., and Mercke, C. Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers. Int. J. Radiat. Oncol. Biol. Phys., 46: 13-19, 2000.
31. Taghian, A., Ramsay, J., Allalunis-Turner, J., Budach, W., Gioioso, D., Pardo, F., Okunieff, P., Bleehen, N., Urtasun, R., and Suit, H. Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys., 25: 243-249, 1993.
32. Wouters, B. G., Weppler, S. A., Koritzinsky, M., Landuyt, W., Nuyts, S., Theys, J., Chiu, R. K., and Lambin P. Hypoxia as a target for combined modality treatments. Euro. J. Cancer, 38: 240-257, 2002.
33. Koukourakis, M. I. Tumour angiogenesis and response to radiotherapy. Anticancer Res., 21: 4285-4300, 2001.
34. Pardoll, D. Does the immune system see tumors as foreign or self? Ann. Rev. Immunol., 21: 807-839, 2003.
35. Antognoni, P., Terry, N. H. A., Richetti, A., Luraghi, R., Tordiglione, M., and Danova M. The predictive role of flow cytometry-derived tumor potential doubling time (Tpot) in radiotherapy: open questions and future perspectives. Intl. J. Oncol., 12: 245-256, 1998.
36. Buffa, F. M., Davidson, S. E., Hunter, R. D., Nahum, A. E., and West, C. M. L. Incorporating biologic measurements (SF(2), CFE) into a tumor control probability model increases their prognostic significance: a study in cervical carcinoma treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 50: 1113-1122, 2001.
37. West, C. M., Davidson, S. E., Pool, C., et al. Lack of a relationship between colony-forming efficiency and surviving fraction at 2 Gy. Radiat. Res., 126: 260-263, 1991.